Drug General Information
Drug ID	D01XEQ
Former ID	DCL000945
Drug Name	R348
Indication	Psoriasis [ICD9: 696; ICD10:L40]		Terminated	[537117]
Company	Rigel Pharmaceuticals
Structure		Download 2D MOL 3D MOL
Target and Pathway
Target(s)	Tyrosine-protein kinase JAK3	Target Info	Inhibitor	[537117]
KEGG Pathway	Chemokine signaling pathway
	PI3K-Akt signaling pathway
	Signaling pathways regulating pluripotency of stem cells
	Jak-STAT signaling pathway
	Measles
	HTLV-I infection
	Epstein-Barr virus infection
	Viral carcinogenesis
	Primary immunodeficiency
PANTHER Pathway	Interleukin signaling pathway
	JAK/STAT signaling pathway
	PDGF signaling pathway
Pathway Interaction Database	IL4-mediated signaling events
	CD40/CD40L signaling
	Signaling events mediated by TCPTP
	SHP2 signaling
	IL2-mediated signaling events
	IL2 signaling events mediated by PI3K
	IL2 signaling events mediated by STAT5
Reactome	GPVI-mediated activation cascade
	Interleukin-7 signaling
	G beta:gamma signalling through PI3Kgamma
	Interleukin-2 signaling
	RAF/MAP kinase cascade
	Interleukin receptor SHC signaling
WikiPathways	IL-2 Signaling Pathway
	IL-4 Signaling Pathway
	Interleukin-2 signaling
	Interleukin-7 signaling
	Oncostatin M Signaling Pathway
	IL-9 Signaling Pathway
	IL-7 Signaling Pathway
	Interleukin-3, 5 and GM-CSF signaling
References
Ref 537117	Emerging drugs for psoriasis. Expert Opin Emerg Drugs. 2009 Mar;14(1):145-63.
Ref 537117	Emerging drugs for psoriasis. Expert Opin Emerg Drugs. 2009 Mar;14(1):145-63.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.